PC
IMVT icon

PA Capital’s Immunovant IMVT Stock Holding History

PA Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,871
Closed -$220K – 172
2019
Q4 		$220K Buy
+13,871
New +$155K 0.19% 112

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

PA Capital's IMVT Position: Q1 2020 in Review

PA Capital sold out of Immunovant (IMVT) in Q1 2020, closing a stake of 13,871 shares — an estimated $220K sold.

PA Capital first reported a position in IMVT in Q4 2019 and held it in 1 quarter. The position peaked at $220K in Q4 2019. 40 funds tracked by Wall St. Rank hold IMVT as of Q1 2020.

  • PA Capital reported no remaining Immunovant position as of Q1 2020 after selling out during the quarter.
  • PA Capital sold 13,871 Immunovant shares in Q1 2020, an estimated $220K.
  • PA Capital first reported a position in Immunovant in Q4 2019 and held it in 1 quarter.
  • PA Capital's Immunovant position peaked at $220K in Q4 2019.
  • 40 funds tracked by Wall St. Rank held Immunovant as of Q1 2020.

Based on PA Capital's 13F filing for Q1 2020, filed 11 May 2020.